DRC Ebola outbreak nears record
Analysis based on 410 articles · First reported Jul 06, 2026 · Last updated Jul 28, 2026
The outbreak is disrupting US-backed critical minerals negotiations with DRC, delaying travel and meetings, which could slow efforts to challenge China's dominance in cobalt and copper supply chains. Healthcare stocks and companies involved in Ebola treatments, such as Gilead Sciences and NanoViricides, may see increased investor attention.
The Democratic Republic of the Congo is experiencing its fastest-growing Ebola outbreak on record, caused by the rare Bundibugyo virus for which there is no approved vaccine or treatment. As of July 28, 2026, the Ministry of Public Health reported 3,262 confirmed cases and 1,437 deaths, concentrated in the eastern Ituri province. The outbreak has spread to five provinces and neighboring Uganda, which declared itself Ebola-free after containing imported cases. The World Health Organization warns the true scale may be two to four times larger due to undetected transmission. Response efforts are hampered by health worker strikes over unpaid wages, attacks on health facilities, community mistrust, and ongoing rebel violence involving the March 23 Movement and Syrian Democratic Forces. The United States has restricted direct flights from DRC and delayed negotiations on a critical minerals partnership. Clinical trials for treatments have begun, including the EBO-PEP trial of obeldesivir by Gilead Sciences and a Phase II trial of NV-387 by NanoViricides. University of Oxford has started the first human trial of a Bundibugyo vaccine. The United States — Centers for Disease Control and Prevention warns the outbreak could become one of the worst ever documented.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard